Anthracyclines-paclitaxel combinations in the treatment of breast cancer

被引：15

作者：

Conte, PF

Gennari, A

机构：

[1] U.O. Oncologia Medica, Ospedale Santa Chiara, 56100 Pisa

来源：

ANNALS OF ONCOLOGY | 1997年 / 8卷 / 10期

关键词：

breast cancer; taxol-anthracycline combination;

D O I：

10.1023/A:1008208002779

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：939 / 943

页数：5

共 53 条

[1] CHEMOTHERAPY AND SURVIVAL IN ADVANCED BREAST-CANCER - THE INCLUSION OF DOXORUBICIN IN COOPER TYPE REGIMENS [J].

AHERN, RP ;

SMITH, IE ;

EBBS, SR .

BRITISH JOURNAL OF CANCER, 1993, 67 (04) :801-805

[2] Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro [J].

Akutsu, M ;

Kano, Y ;

Tsunoda, S ;

Suzuki, K ;

Yazawa, Y ;

Miura, Y .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) :2341-2346

[3]

AMADORI D, 1996, ANN ONCOL S11, V23, P16

[4] Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group [J].

Bastholt, L ;

Dalmark, M ;

Gjedde, SB ;

Pfeiffer, P ;

Pedersen, D ;

Sandberg, E ;

Kjaer, M ;

Mouridsen, HT ;

Rose, C ;

Nielsen, OS ;

Jakobsen, P ;

Bentzen, SM .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1146-1155

[5]

BENGALA C, IN PRESS CANCER

[6] PHARMACOKINETICS OF TAXOL AND DOXORUBICIN ADMINISTERED ALONE AND IN COMBINATION BY CONTINUOUS 72-HOUR INFUSION [J].

BERG, SL ;

COWAN, KH ;

BALIS, FM ;

FISHERMAN, JS ;

DENICOFF, AM ;

HILLIG, M ;

POPLACK, DG ;

OSHAUGHNESSY, JA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (02) :143-145

[7] DRUGS 10 YEARS LATER - EPIRUBICIN [J].

BONADONNA, G ;

GIANNI, L ;

SANTORO, A ;

BONFANTE, V ;

BIDOLI, P ;

CASALI, P ;

DEMICHELI, R ;

VALAGUSSA, P .

ANNALS OF ONCOLOGY, 1993, 4 (05) :359-369

[8]

BONNETERRE J, 1996, P AN M AM SOC CLIN, V15, P82

[9] Doubling epirubicin dose intensity (100 mg/m(2) versus 50 mg/m(2)) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer [J].

Brufman, G ;

Colajori, E ;

Ghilezan, N ;

Lassus, M ;

Martoni, A ;

Perevodchikova, N ;

Tosello, C ;

Viaro, D ;

Zielinski, C ;

Krainer, M ;

Salzer, H ;

Schuller, J ;

Dittrich, C ;

Scheithauer, W ;

Zamagni, C ;

Ambrosini, G ;

Colucci, G ;

Gentilini, P ;

Zaniboni, A ;

Pacini, P ;

Bianco, R ;

Mustacchi, G ;

DAprile, M ;

DeMatteis, A ;

Oliveira, C ;

Jordaan, J ;

Gudgeon, A ;

VanZyl, J ;

Rakowsky, E ;

Inbar, M ;

Rath, P ;

Cohen, Y ;

Shani, A ;

Fried, G ;

Hegg, R ;

Neto, AB ;

Bader, G ;

Braga, RF ;

Vitoc, C ;

Puerto, VML ;

Valle, AE ;

Salazar, JD ;

Sanchez, JC ;

Villela, GM ;

Fountzilas, G .

ANNALS OF ONCOLOGY, 1997, 8 (02) :155-162

[10]

BURGEOIS H, 1996, P AN M AM SOC CLIN, V15, P258

← 1 2 3 4 5 6 →